Table 1.

Summarization of ongoing CRISPR related clinical trials

Classification	Identifier	Targeted disease	Targeted gene	Start date	Intervention/treatment	Estimated enrollment	Phase
CRISPR/Cas9	NCT02793856	Metastatic non-small cell lung cancer	Programmed cell death protein 1(PDCD1) gene	August 28, 2016	Autologous CRISPR Cas9 mediated PD-1 Knockout T cells	12	Phase 1
	NCT03044743	Advanced Stage EBV Associated Malignancies	PD-1	April 7, 2017	CRISPR-Cas9 mediated PD-1 knockout-T cells from autologous origin	20	Phase 1/2
	NCT03164135	HIV-infected Subjects With Hematological Malignances	CCR5	May 30, 2017	CD34 + hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene	5	–
	NCT03166878	Relapsed or Refractory CD19 + Leukemia and Lymphoma	CD19	June 2017	Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19	80	Phase 1/2
	NCT03398967	Relapsed or Refractory B Cell Leukemia and Lymphoma	CD19 and CD20 or CD22	January 2, 2018	Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22	80	Phase 1/2
	NCT03545815	Mesothelin Positive Multiple Solid Tumors	PD-1 and TCR	March 19, 2018	CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells	10	Phase 1
	NCT03747965	Mesothelin Positive Multiple Solid Tumors	PD-1	November 2018	CRISPR-Cas9 Mediated PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells	10	Phase 1
	NCT04417764	Advanced Hepatocellular Carcinoma	PD-1	June 20, 2019	Autologous PD-1 Knockout CRISPR-Cas9-Engineered T Cells	10	Phase 1
	NCT04035434	Relapsed or Refractory B-Cell Malignancies	CD19	July 22, 2019	CD19-directed Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110)	143	Phase 1
	NCT04244656	Relapsed or Refractory Multiple Myeloma	BCMA (B-cell maturation antigen)	January 22, 2020	Anti-BCMA(B-cell maturation antigen) Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120)	80	Phase 1
	NCT04213469	Relapse/Refractory B-cell Lymphoma	PD1 and CD19	March 13, 2020	PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells	20	–
	NCT04426669	Metastatic Gastrointestinal Epithelial Cancer	CISH (Cytokine-induced SH2 protein)	May 15, 2020	Autologous CISH (Cytokine-induced SH2 protein) inactivated CRISPR-Cas9-Engineered Tumor-Infiltrating Lymphocytes	20	Phase 1/2
	NCT04438083	Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation	CD70	June 16, 2020	CD70-directed Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130)	107	Phase 1
	NCT04502446	Relapsed or Refractory T or B Cell Malignancies	CD70	July 31, 2020	Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130)	45	Phase 1
CRISPR/Cas12	NCT05447169	Nasopharyngeal Carcinoma	Epstein-Barr virus DNA	July 10, 2022	Quantitative polymerase chain reaction and Cas 12a target sequencing of EBV DNA in nasopharyngeal brushing and plasma	11,625	–